Nasus Pharma Ltd (NSRX) stock
NSRXNYSEPharmaceutical PreparationsFiscal year ends December 31
$2.87+0.05 (+1.77%)
Close on Nov 13, 2026Market cap $25.87MP/E –Yield –
Nasus Pharma EPS
Diluted earnings per share is net income divided by the share count including options and convertible securities.
For fiscal 2025 it was -$0.72.
Annual eps
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$0.72 | – |
| FY2024 | Dec 31, 2024 | -$0.22 | – |
| FY2023 | Dec 31, 2023 | -$0.20 | – |
- Revenue
- Gross Profit
- Operating Income
- Net Income
- EBITDA
- Free Cash Flow
- Operating Cash Flow
- R&D Expenses
- Gross Margin
- Operating Margin
- Profit Margin
- Total Debt
- Cash
- Total Assets
- Shares Outstanding
- Market Cap
- Enterprise Value
- PE Ratio
- Price to Sales Ratio
- Price to Book Ratio
- EV/EBITDA
- Price to Free Cash Flow
- All statistics
See a number that looks wrong?